These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15621223)

  • 1. The patient's perspective: redefining end points.
    Palmtag H
    Urology; 2004 Dec; 64(6 Suppl 1):17-20. PubMed ID: 15621223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women.
    Kim YH; Seo JT; Yoon H
    Int J Impot Res; 2005; 17(2):158-63. PubMed ID: 15510187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?
    Van Brummen HJ; Bruinse HW; Van de Pol G; Heintz AP; Van der Vaart CH
    BJU Int; 2006 Feb; 97(2):296-300. PubMed ID: 16430633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Pathophysiology and treatment of the overactive bladder"].
    Yokoyama O
    Hinyokika Kiyo; 2005 Sep; 51(9):599-601. PubMed ID: 16229372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
    Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
    BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
    Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
    Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
    Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
    BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the urgency perception scale.
    Cardozo L; Coyne KS; Versi E
    BJU Int; 2005 Mar; 95(4):591-6. PubMed ID: 15705086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.